Endpoints News 生物医药· Nicole DeFeudis·· 26 天前精选AI 评分68
ivonescimab胆道癌III期临床试验结果公布及与Keytruda对比分析
#ESMO26: Akeso details ivonescimab's biliary cancer success, drawing Keytruda comparisons
AI 导读
ivonescimab在胆道癌III期临床试验中显示中位总生存期(OS)和疾病进展间隔(PFS)优势,Akeso与Summit Therapeutics公布该中国专属适应症数据,并与Keytruda疗效指标形成对比。原文未提供具体数值,但明确提及试验为随机对照试验(RCT)。
推荐理由
ivonescimab在胆道癌III期临床试验中显示生存期优势,与Keytruda的对比为后续适应症拓展提供参考视角。
正文
MADRID — Akeso on Sunday spelled out by how much its Summit Therapeutics-partnered PD-1xVEGF bispecific improved survival in a late-stage, China-only biliary tract cancer study …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news